SPECT IMAGING OF DOPAMINE D2-RECEPTORS WITH I-123 IBZM - INITIAL EXPERIENCE IN CONTROLS AND PATIENTS WITH PARKINSONS SYNDROME AND WILSONS-DISEASE

被引:86
作者
TATSCH, K
SCHWARZ, J
OERTEL, WH
KIRSCH, CM
机构
[1] Division of Nuclear Medicine, Department of Radiology
[2] Division of Nuclear Medicine, Department of Neurology, Klinikum Grosshadern, University of Munich, Munich 70, 8000
关键词
D O I
10.1097/00006231-199108000-00005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
I-123-(S-)-2-hydroxy-3-iodo-6-methoxy-N[(1-ethyl-2-pyrrolidinyl) methyl]-benzamide (I-123-IBZM) is a highly selective CNS D2 dopamine receptor ligand suitable for SPECT. This study reports on IBZM-SPECT findings in 60 patients including eight controls and 52 patients presenting with disorders of the dopaminergic system, including idiopathic Parkinson's syndrome (IPS) (n = 18), Parkinson's syndromes of other aetiology (PS) (n = 24) and Wilson's disease (n = 10). SPECT was performed 2 h p.i. of 185 MBq I-123-IBZM. For semiquantitative evaluation basal ganglia to frontal cortex ratios (BG/FC ratios) were calculated. In controls BG/FC ratios of 1.55 +/- 0.05 S.D. were observed. Findings in IPS patients (BG/FC ratio: 1.51 +/- 0.05) were not different from controls. In PS patients striatal IBZM binding (BG/FC ratio: 1.35 +/- 0.11) was significantly (P < 0.001) lower compared to the control and IPS groups. Asymptomatic patients with Wilson's disease presented normal IBZM binding. In those with neurologic symptoms IBZM fixation was markedly reduced. IBZM-SPECT has shown to be a suitable means for in vivo imaging of striatal dopamine D2 receptors in controls and various disorders of the dopaminergic system. Our preliminary data suggest that IBZM-SPECT is potentially useful for discriminating between IPS and PS (sensitivity: 100%; specificity: 83%). In patients with Wilson's disease IBZM accumulation seems to correlate with the presence of neurologic symptoms.
引用
收藏
页码:699 / 707
页数:9
相关论文
共 13 条
  • [1] Kung H.F., Pan S., Kung M.-P., Kasliwal R., Reilly J., Alavi A., In vitro and in vivo evaluation of [123I]IBZM: A potential CNS D-2 dopamine receptor imaging agent, J Nucl Med, 30, pp. 88-92, (1989)
  • [2] Kung H.F., Alavi A., Chang W., Kung M.-P., Keyes J.W., Velchik M.G., Billings J., Pan S., Noto R., Rausch A., Reilly J., In vivo SPECT imaging of CNS D-2 dopamine receptors: Initial studies with iodine-123-IBZM in humans, J Nucl Med, 31, pp. 573-579, (1990)
  • [3] Costa D.C., Verhoeff N., Cullum I.D., Ell P.J., Syed G., Barrett J., Palazidou E., Toone B., Van Royen E., Bobeldijk M., In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans, Eur J Nucl Med, 16, pp. 813-816, (1990)
  • [4] Verhoeff N., Costa D.C., Ell P.J., Toone B., Palasidoun E., Cullum I.D., Bobeldijk M., Syed G., Van Royen E.A., Assessment of dopamine D2-receptor density and occupancy in patients with schizophrenia with and without neuroleptics using 1-123 IBZM SPECT, Eur J Nucl Med, 16, (1990)
  • [5] Verhoeff N., Speelman J.D., Van Royen E.A., De Jong J., In vivo dopamine D2- receptors imaging with 1-123 iodobenzamide SPECT in patients with multiple system atrophy, Eur J Nucl Med, 16, (1990)
  • [6] Verhoeff N., Costa D.C., Miller R., Ell P.J., Cullum I.D., Bobeldijk M., Wijnhoven G., Van Royen E.A., Assessment of dopamine D2-receptor density in patients with AIDS using 1-123 IBZM SPECT, Eur J Nucl Med, 16, (1990)
  • [7] Brucke T., Podreka I., Angelberger P., Aschauer H., Topitz A., Deecke L., Dopamine D2 receptor imaging with SPECT in patients with extrapyramidal disorders, psychosis and under neuroleptic treatment, Eur J Nucl Med, 16, (1990)
  • [8] Stirner H., Picker D., Brauner B., Standardisierte Dokumentation und Quantifizierung der HMPAO-Hirnperfusionstomographie (SPECT), Nucl Med, 28, (1989)
  • [9] Chang L.T., A method for attenuation correction in radionuclide computed tomography, IEEE NS, 25, pp. 638-639, (1978)
  • [10] Fleming J.S., A technique for using CT images in attenuation correction and quantification in SPECT, Nucl Med Commun, 10, pp. 83-97, (1989)